Use of any vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) within  weeks of initiation of study treatment.
Within  days of treatment initiation:\r\nPlatelets >= ,/mcL
The patients' last dose of chemotherapy must be at least  weeks prior to initiation of study therapy
Treatment with radiation therapy within  weeks prior to the initiation of study drug.
Within  days of treatment initiation:\r\nPlatelets >= ,/mcL
Treatment with investigational therapy within  days prior to initiation of study treatment
Patients who have had chemotherapy (e.g., purine analogues, alkylating agents), radiation therapy, or participation in any investigational drug treatment within  weeks of initiation of DMF or at any time during the study
No prior lapatinib within  days prior to initiation of protocol treatment
Treatment with investigational therapy within  days prior to initiation of study treatment
Had immunotherapy, radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or treatment with an investigational product within  weeks prior to treatment initiation (or oral therapy within  week prior to treatment initiation).
Treatment with radiation therapy within  weeks prior to the initiation of study drug administration.
Participant is able to complete a minimum of  days of study agent dosing prior to initiation of definitive treatment for their cancer
Use of any vaccines against infectious diseases within  weeks of initiation of study treatment.
Investigational therapy within  days prior to initiation of study treatment
Patients who have had chemotherapy (e.g., purine analogues, alkylating agents), immunotherapy, radiation therapy, or participation in any investigational drug treatment within  weeks of initiation of UC-, or at any time during the study
Between days  and  post transplantation at the time of initiation of the study drug
Patients must be off all disease modifying therapy for MDS for  days prior to initiation of study treatment; patients may receive hydrocortisone prophylactically to prevent transfusion reactions
Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within  weeks ( weeks for nitrosoureas) prior to initiation of therapy. The use of live vaccines within  days before initiation of therapy. IMiDs, PIs and or corticosteroids within  weeks prior to initiation of therapy. Other investigational therapies and monoclonal antibodies (mAb) within  weeks of initiation of therapy Prednisone up to but no more than  mg orally once daily (q.d.) or its equivalent for symptom management of comorbid conditions is permitted but dose should be stable for at least  days prior to initiation of therapy
Prior major surgical procedure or radiation therapy within  weeks of initiation of therapy (this does not include limited course of radiation used for management of bone pain within  days of initiation of therapy)
Treatment with any of the drugs listed in Section .. at the time of study treatment initiation.
Treatment with any, investigational therapy within the  weeks prior to the initiation of study drug administration
Administration of investigational agents within  days prior to treatment initiation
Indication for initiation of therapy
Herbal preparations are not allowed throughout the study, and should be discontinued  days prior to initiation of study treatment
Have received any unapproved agent or device within  days before initiation of study treatment.
All patients must discontinue anti-platelet agents or anticoagulants  days prior to initiation of study drug
Current or previous treatment with investigational therapy in another therapeutic clinical trial interrupted less than  weeks before study treatment initiation.
Use of any vaccines against infectious diseases (e.g. varicella, pneumococcus) within  weeks of initiation of study treatment.
Patient received investigational treatment within  weeks or immunotherapy or antibody therapy within  days prior to initiation of treatment with Toca , and/or has not recovered from toxicities associated with such treatment.
Surgery prior to enrollment within  days prior to the initiation of study treatment or unhealed surgical incision;
Patients must have stable topical medication regimen for  weeks prior to study initiation
History of treatment with canakinumab within the  months prior to study initiation
History of phototherapy within  weeks prior to study initiation
Loco-regional treatment within  weeks prior to initiation of study treatment.
Any anti-lymphoma treatment within  months of treatment initiation.
Last chemotherapy at least  weeks from initiation of study treatment
Treatment with systemic immunosuppressive medication within  weeks prior to initiation of study
Have received any unapproved agent or device within  days before initiation of study treatment.
Treatment with radiation therapy within  weeks prior to the initiation of study drug administration.
Received the following within  days prior to the initiation of study treatment:
Treatment with investigational therapy within  days prior to initiation of study drug
Investigational therapy within  days prior to initiation of study treatment
Any cytotoxic or biologic therapy less than  weeks prior to initiation of therapy.
Therapy with other investigational agents within  weeks of treatment initiation on this trial
Immunosuppressive therapy within  days prior to initiation of protocol therapy
Immunosuppressive therapy within  days prior to initiation of protocol therapy
Prior recent systemic or investigational therapy within  days of initiation of study treatment; an exception is that EGFR inhibitor may be continued up until  days of initiation of study treatment
Participant treated with any prior systemic therapy for myeloma; treatment by localized radiotherapy is not an exclusion criterion if an interval of at least  days between the end of radiotherapy and initiation of protocol therapy is observed; intervals of less than  days between radiotherapy and initiation of protocol therapy will be considered on a case by case basis with the lead principal investigator (PI), provided toxicity is not a concern; similarly, the dose of corticosteroids received by the participant as part of initial therapy for myeloma should not exceed the equivalent of  mg of dexamethasone over a two-week period before initiation of protocol therapy
Subjects who have completed sipuleucel-T (Provenge ) treatment within  days of study drug initiation.
Radiotherapy within the  weeks before initiation of treatment. Palliative radiation treatment to nonindex or bone lesions performed less than  weeks before treatment initiation may be considered with medical monitor approval
Participant treated with any prior systemic therapy with the exception of the following:\r\n* Treatment by localized radiotherapy for a specific indication within  weeks of initiation of treatment\r\n* Treatment with corticosteroids, not to exceed the equivalent of  mg of dexamethasone over a four-week period before initiation of protocol therapy
Patients who have received chemotherapy within  weeks prior to the initiation of study treatment, or endocrine therapy within  weeks prior to the initiation of study treatment; if patients are already on trastuzumab, this medication may be continued
Patients who have participated in a prior investigational study within  weeks prior to initiation of study treatment
Toxicities due to prior cancer therapy that have not resolved before the initiation of study treatment, if the Investigator determines that the continuing complication will compromise the safe treatment of the patient
Treatment with chemotherapy (other than high-dose chemotherapy as described above) or differentiation therapy (such as retinoic acid) or immunotherapy (such as anti-GD antibody treatment) within  weeks prior to initiation of study drug or, if treatment included nitrosoureas, within  weeks prior to initiation of study drug
Treatment with investigational therapy (with the exception of cancer therapies as described above) within  weeks prior to initiation of study drug
Treatment with herbal cancer therapy within  week prior to initiation of study drug
Treatment for the studied cancer within  days prior to initiation of study treatment
Treatment with investigational therapy within  days prior to initiation of study treatment
Use of any vaccines against infectious diseases (e.g., influenza, varicella, etc.) within  weeks ( days) of initiation of study therapy and  days after the last administration of the study medication.
Any investigation agents must be discontinued at least  days prior to study treatment initiation
Participation in an investigational anti-cancer study within  weeks prior to initiation of therapy
Subjects must be off any steroids  days prior to the initiation of treatment
Positive culture for or other clinical evidence of infection with bacteria or fungus within  days of the initiation of study treatment
Subjects must not have received other antineoplastic agents with therapeutic intent, excluding hydroxyurea and antimetabolites administered as part of maintenance chemotherapy, within  days prior to study treatment initiation
Patients who have received chemotherapy or radiotherapy within  weeks prior to enrollment are NOT eligible for participation \r\n* The exception to this is patients who are refractory to conventional initial induction chemotherapy (=<  courses) or to radiation; patients must have morphologic proof (from bone marrow aspirate, smears, or touch preps of marrow biopsy) of AML with > % blasts within  weeks prior to initiation of study therapy\r\n* The last dose of cytotoxic therapy (NOT including Hydrea, which is allowed) must have been given >=  days prior to initiation of study therapy\r\n* The last dose of biologic therapy must have been given >=  days prior to initiation of study therapy\r\n* The last dose of any investigational agent must have been given >=  days prior to initiation of study therapy
Treatment initiation with BST no longer than  months prior to randomization
Within  weeks of treatment initiation (day ), have received treatment with:\r\n* Imiquimod\r\n* Total body electron beam radiation\r\n* Investigational drugs or treatments
Radiation therapy within  weeks prior to initiation of study treatment
Interval >=  weeks between open brain biopsy and initiation of protocol-based therapy
Date of randomization must be within  weeks of initiation of optimal systemic therapy
Patients must be off all \statin\ drugs for ? weeks prior to initiation of therapy.
History of receiving any investigational treatment within  days of study medication initiation
Patients who have received prior lenalidomide therapy are not eligible for this study; further there should be at least a -day window from the patients last prior therapy before initiation of treatment on clinical trial
Initiation of anti-tumor therapy including chemotherapy or investigational drug treatment within  days before beginning study
Patients may not have had radiation therapy within the last  weeks prior to initiation of study treatment.
Patients must not have the following foods/ supplements at least  days prior to initiation of and during study treatment:
Initiation of a new drug therapy within the past  days prior to study commencement
All patients are expected to be followed for at least  year after the initiation of therapy
All pre-treatment laboratory tests and scans must be performed within  days prior to initiation of treatment
Treatment with any anti-cancer therapy within  weeks prior to initiation of study treatment
Treatment with any anti-cancer therapy within  weeks prior to initiation of study treatment
No immunosuppressive therapy within  days prior to initiation of protocol therapy
Bilirubin =< . x ULN, within  days prior to initiation of study drug
Subjects who received any of the following within the last  days of initiation of study treatment: ) Plasmapheresis, ) Major surgery, ) Radiation therapy, ) Use of any anti-myeloma drug therapy
The last dose of biologic or investigational therapy must be =<  days prior to initiation of study therapy
Patient participants must be at a point of treatment initiation/change or evaluation for treatment initiation/change
Within the first  weeks of initiation of a new type of therapy
Use of any vaccines against infectious diseases (e.g. varicella, pneumococcus) within  weeks of initiation of study treatment.
Initiation of investigational agent =<  days after initiation of radiotherapy
Patients must be able to complete the baseline S FACT EGFRI  within  days prior to initiation of EGFRI therapy
Initiation of hormone therapy <  weeks prior to enrollment in the study
Anticipated initiation of cetuximab treatment with or without additional chemotherapy
Use of any systemic antifungal therapy for >  hours during the week prior to study drug initiation
Has vomited in the  hours prior to chemotherapy initiation on Treatment Day 
Had at least  days for prior treatment to clear the body before initiation of DS-b administration (except for hydroxyurea that needs only  days for clearance)
Discontinuation of all other therapies (including radiotherapy or chemotherapy) for the treatment of iNHL >=  weeks before initiation of study treatment
Have discontinued all disease-modifying therapy for the primary cancer for  days prior to initiation of study treatment.
Baseline (prior to the initiation of new ET), and;
Subsequently at , ,  and  months after the initiation of therapy, and/or;
Pregnant or actively breastfeeding without intention to discontinue prior to initiation of study
